Cargando…

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient

We report the first case of miltefosine rescue treatment carried out for visceral leishmaniasis (VL) relapse patient. Despite undergoing treatment regimens of liposomal amphotericin B (LAMB) 5 mg/kg (standard: 10 mg/kg) daily for 3 days during the first episode followed by LAMB 5 mg/kg stat and paro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bastola, Anup, Shrestha, Mitesh, Chalise, Bimal Sharma, Mishra, Abhdesh Kumar, Devkota, Lina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745118/ https://www.ncbi.nlm.nih.gov/pubmed/31565448 http://dx.doi.org/10.1155/2019/3634568

Ejemplares similares

Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis
por: Koley, Sankha, et al.
Publicado: (2013)

Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B
por: McQuarrie, Shauna, et al.
Publicado: (2015)

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
por: Srivastava, Saumya, et al.
Publicado: (2017)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
por: Ferreira, Carolina, et al.
Publicado: (2020)

Relapse after Treatment with Miltefosine for Visceral Leishmaniasis Is Associated with Increased Infectivity of the Infecting Leishmania donovani Strain
por: Rai, Keshav, et al.
Publicado: (2013)

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
por: Patra, Pradyumna, et al.
Publicado: (2012)

Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia
por: Ostyn, Bart, et al.
Publicado: (2014)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis
por: Bhandari, Vasundhra, et al.
Publicado: (2012)

A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
por: Carnielli, Juliana B.T., et al.
Publicado: (2018)

Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis
por: Melcon-Fernandez, Estela, et al.
Publicado: (2023)

Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2015)

Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
por: dos Santos Nogueira, Fabio, et al.
Publicado: (2019)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Clinical and Laboratory Response of Domiciled Dogs with Visceral Leishmaniasis Treated with Miltefosine and Allopurinol
por: Vaz, Talita Pereira, et al.
Publicado: (2023)

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
por: Kassam, K., et al.
Publicado: (2013)

Natural Resistance of Leishmania infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil
por: Carnielli, Juliana B. T., et al.
Publicado: (2019)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Persistent Symptoms in Post-COVID-19 Patients Attending Follow-Up OPD at Sukraraj Tropical and Infectious Disease Hospital (STIDH), Kathmandu, Nepal
por: Bastola, Anup, et al.
Publicado: (2021)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

Cutaneous Leishmaniasis of Lip and Role of Polymerase Chain Reaction: A Case Report
por: Parajuli, Niraj, et al.
Publicado: (2020)

Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh
por: Mondal, Dinesh, et al.
Publicado: (2019)

A case of canine visceral leishmaniasis of unknown origin in Curitiba (state of Paraná, Brazil) treated successfully with miltefosine
por: Gonçalves, Gustavo, et al.
Publicado: (2023)

Combination of Liposomal CpG Oligodeoxynucleotide 2006 and Miltefosine Induces Strong Cell-Mediated Immunity during Experimental Visceral Leishmaniasis
por: Shivahare, Rahul, et al.
Publicado: (2014)

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
por: Sundar, Shyam, et al.
Publicado: (2007)

Miltefosine for the treatment of cutaneous leishmaniasis—A pilot study from Ethiopia
por: van Henten, Saskia, et al.
Publicado: (2021)

Visceral leishmaniasis with Roth spots
por: Meena, Jagdish, et al.
Publicado: (2014)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
por: Mondal, Dinesh, et al.
Publicado: (2019)

Tuberous sclerosis with visceral leishmaniasis: a case report
por: Pandey, Krishna, et al.
Publicado: (2009)

Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis
por: Pandey, Krishna, et al.
Publicado: (2020)

Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis
por: Proverbio, Daniela, et al.
Publicado: (2016)

1662. Pushing the Dose: Miltefosine Treatment for a Supersized American with Cutaneous Leishmaniasis
por: Aronson, Naomi E, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial
por: Mbui, Jane, et al.
Publicado: (2019)

Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario
por: Pandey, Krishna, et al.
Publicado: (2009)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_do1a3ie582ndq6cucqq84ldv3m